Thank you for Subscribing to Life Science Review Weekly Brief
Merakris Therapeutics has signed an agreement with Miracles In Sight (MIS) to provide Opticyte Amniotic Ophthalmic Repair Grafts to MIS-affiliated eye doctors in three states.
FREMONT, CA: Merakris Therapeutics, based in Research Triangle Park, has signed an agreement with Miracles In Sight (MIS) to provide Opticyte Amniotic Ophthalmic Repair Grafts to MIS-affiliated eye doctors in three states.
One of the largest non-profit eye banks globally, MIS offers highly advanced corneal tissue for transplantation to restore, preserve, and improve vision. The North Carolina-based company Winston-Salem collaborates with worldwide innovators to test novel techniques and solutions that address emerging ophthalmic concerns. Through the Merakris collaboration, MIS is connected with more than 70 eye clinics in North and South Carolina and Texas, who will now have easy access to Opticyte.
The Opticyte Amniotic Ophthalmic Repair Grafts are a biological barrier that shields the eye's corneal surface while recovering and helps avoid scar tissue formation.
The substance promotes cell adhesion and ingrowth, and it's frequently employed as an additional biological barrier in individuals with dry eye disease or other corneal abnormalities. The grafts, made from an amniotic membrane, come in several shapes and sizes to meet various surgical demands.
"We are excited to begin this new partnership with Miracles In Sight as we continue to grow through new additions to the Merakris family of products," said Chris Broderick, the company's CEO. "During the past year we have launched Opticyte through a variety of channels, ranging from business-to-business sales to strategic partnerships like this one. We know the MIS team well and we are eager to fully support their clinics across these three service areas."
"At Miracles in Sight, our mission is to support the restoration, preservation and enhancement of site," said Kristen McCoy, vice president of Surgical Applications. "This partnership aligns with our mission and allows us to expand our service options. We are excited to work with Merakris to make the Opticyte product available to our community of physicians."